The latest learning and CPD content on cancer. Under ‘Other resources’ you will find all our other content related to cancer.
CPD and Learning
Access to colorectal cancer screening varies across the UK. This article describes the various tests and how community pharmacists can promote them.
This article provides practical advice to support pharmacy professionals in their duty of care to recognise and refer patients with ‘red flag’ cancer symptoms.
Lung cancer: advances in management and therapySubscription
An overview of traditional and emerging immunotherapy-based targets and treatments available for lung cancer, their side effects and the impact immune checkpoint inhibitors have had on the treatment of non–small-cell lung cancer.
These treatments are commonly associated with autoimmune-related side effects and toxicities. This article outlines how pharmacists and the pharmacy team can recognise and manage these adverse events.
Melanoma is the fifth most common cancer in the UK, accounting for 4% of all new cancer diagnoses. Pharmacists and healthcare professionals are ideally placed to offer advice to patients on the use of sunscreens to limit UV exposure, reducing their risk of developing melanoma.
Patients with advanced melanoma treated with a combination of ipilimumab and nivolumab are more likely to be alive five years later than patients treated with ipilimumab alone or nivolumab alone.
An overview of the anticancer agents that have been approved for use in the UK as part of a precision medicine approach for solid tumours, along with information relating to the relevant biomarkers and biomarker assays currently available.
Oral antibiotic use is linked to an increased risk of colon cancer, but a reduced risk of rectal cancer, a study in Gut suggests.
Patients treated with nivolumab for advanced non-small cell lung carcinoma had a better survival rate at five years than those who received chemotherapy, a follow-up trial has shown.
Chemotherapy more effective than second targeted hormone therapy in resistant prostate cancerSubscription
Men with advanced prostate cancer who stop responding to targeted hormone therapy but are then treated with modern chemotherapy have better survival rates than those given a second targeted treatment, a study published in the New England Journal of Medicine has shown.
Patients with metastatic colorectal cancer who have a BRAF mutation have improved survival after treatment with three targeted therapies instead of standard chemotherapy, results from a phase III trial have shown.
A review of the pros and cons of oral anticancer drug therapy, as well as the pharmacokinetic barriers and potential solutions to oral chemotherapy in the home.
Patients with cancer who use medical cannabis to treat symptoms, such as pain and neuropathy, tend to favour formulations with a higher ratio of the psychoactive component, tetrahydrocannabinol, compared with non-cancer patients.